Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology76
Targeted Therapy & Precision Oncology94
Cell & Gene Therapy for Cancer34
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $0.8t | $925.92 | +2.4% | 3.3M |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.6t | $233.90 | -0.3% | 8.9M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $377.0b | $208.56 | -0.2% | 9.0M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $300.7b | $204.95 | +2.2% | 1.2M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $292.0b | $119.00 | +3.1% | 16.2M |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $188.1b | $355.24 | +1.7% | 3.7M |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $169.2b | $137.64 | -0.7% | 7.3M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $122.0b | $60.29 | +2.3% | 11.5M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $79.2b | $750.74 | +0.6% | 513.0K |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $26.5b | $208.62 | +6.4% | 1.4M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $19.9b | $50.00 | +3.1% | 3.0M |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $19.1b | $53.73 | -1.7% | 13.6M |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $18.4b | $148.62 | -0.4% | 4.8M |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $18.0b | $97.81 | +2.6% | 1.5M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $11.3b | $90.33 | +5.4% | 2.6M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $11.3b | $203.41 | +2.8% | 634.8K |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $10.9b | $44.90 | +1.2% | 2.5M |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $7.6b | $107.64 | +3.6% | 772.5K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $7.4b | $69.29 | +4.0% | 1.7M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $6.8b | $7.68 | +5.9% | 21.5M |
 ACLX | Arcellx, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $6.7b | $115.06 | -0.0% | 479.5K |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.7b | $37.24 | +2.9% | 3.9M |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $5.4b | $73.42 | +10.7% | 1.8M |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $5.2b | $122.41 | -2.3% | 492.5K |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $4.8b | $21.14 | +3.7% | 1.1M |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $4.8b | $83.83 | -0.1% | 549.7K |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.6b | $19.00 | +4.3% | 5.3M |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $4.1b | $46.15 | +5.0% | 1.7M |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $3.2b | $80.01 | +1.5% | 493.9K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.8b | $33.90 | +4.3% | 1.6M |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $2.7b | $26.65 | +6.4% | 2.9M |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $2.6b | $24.25 | +2.8% | 695.7K |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $2.4b | $33.79 | +2.3% | 1.7M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.47 | +0.1% | 2.2M |
 IMNM | Immunome, Inc. | Radiopharmaceuticals & ADCsTargeted Therapy & Precision Oncology | $2.2b | $24.63 | +5.9% | 1.0M |
 SNDX | Syndax Pharmaceuticals, Inc. | Immunotherapy & Immuno-Oncology | $2.0b | $24.20 | +1.7% | 1.7M |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $2.0b | $14.49 | +2.9% | 1.6M |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $1.9b | $51.67 | +4.5% | 740.5K |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $1.9b | $84.80 | +1.0% | 508.0K |
 TYRA | Tyra Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.9b | $35.57 | +1.3% | 1.3M |
 ZYME | Zymeworks Inc. | Targeted Therapy & Precision Oncology | $1.8b | $27.81 | +2.2% | 487.3K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.7b | $16.75 | +4.0% | 2.4M |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $1.5b | $17.50 | +4.9% | 853.5K |
 DMRA | Damora Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.5b | $26.98 | -0.1% | 388.9K |
 NUVB | Nuvation Bio Inc. | Targeted Therapy & Precision Oncology | $1.4b | $5.06 | +5.3% | 2.7M |
 NTLA | Intellia Therapeutics, Inc | Cell & Gene Therapy for Cancer | $1.4b | $14.95 | +5.6% | 3.1M |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $1.4b | $3.85 | +1.3% | 10.7M |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.4b | $10.75 | +5.1% | 1.7M |
 VIR | Vir Biotechnology, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.4b | $10.75 | +4.1% | 2.4M |
 IMTX | Immatics N.V. Ordinary Shares | Immunotherapy & Immuno-OncologyCell & Gene Therapy for Cancer | $1.2b | $11.18 | +2.9% | 358.3K |